182 related articles for article (PubMed ID: 15607962)
1. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation.
Boxer RB; Jang JW; Sintasath L; Chodosh LA
Cancer Cell; 2004 Dec; 6(6):577-86. PubMed ID: 15607962
[TBL] [Abstract][Full Text] [Related]
2. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.
Toyo-oka K; Bowen TJ; Hirotsune S; Li Z; Jain S; Ota S; Escoubet-Lozach L; Garcia-Bassets I; Lozach J; Rosenfeld MG; Glass CK; Eisenman R; Ren B; Hurlin P; Wynshaw-Boris A
Cancer Res; 2006 Jun; 66(11):5565-73. PubMed ID: 16740691
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.
Akli S; Van Pelt CS; Bui T; Multani AS; Chang S; Johnson D; Tucker S; Keyomarsi K
Cancer Res; 2007 Aug; 67(15):7212-22. PubMed ID: 17671189
[TBL] [Abstract][Full Text] [Related]
4. Cooperation of TGF alpha and c-Myc in mouse mammary tumorigenesis: coordinated stimulation of growth and suppression of apoptosis.
Amundadottir LT; Nass SJ; Berchem GJ; Johnson MD; Dickson RB
Oncogene; 1996 Aug; 13(4):757-65. PubMed ID: 8761297
[TBL] [Abstract][Full Text] [Related]
5. Developmental stage determines the effects of MYC in the mammary epithelium.
Blakely CM; Sintasath L; D'Cruz CM; Hahn KT; Dugan KD; Belka GK; Chodosh LA
Development; 2005 Mar; 132(5):1147-60. PubMed ID: 15689376
[TBL] [Abstract][Full Text] [Related]
6. Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis.
Pelengaris S; Abouna S; Cheung L; Ifandi V; Zervou S; Khan M
BMC Biol; 2004 Dec; 2():26. PubMed ID: 15613240
[TBL] [Abstract][Full Text] [Related]
7. Oncogene addiction: sometimes a temporary slavery.
Jonkers J; Berns A
Cancer Cell; 2004 Dec; 6(6):535-8. PubMed ID: 15607957
[TBL] [Abstract][Full Text] [Related]
8. Rehabilitation of cancer through oncogene inactivation.
Shachaf CM; Felsher DW
Trends Mol Med; 2005 Jul; 11(7):316-21. PubMed ID: 15955741
[TBL] [Abstract][Full Text] [Related]
9. Sustained loss of a neoplastic phenotype by brief inactivation of MYC.
Jain M; Arvanitis C; Chu K; Dewey W; Leonhardt E; Trinh M; Sundberg CD; Bishop JM; Felsher DW
Science; 2002 Jul; 297(5578):102-4. PubMed ID: 12098700
[TBL] [Abstract][Full Text] [Related]
10. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.
D'Cruz CM; Gunther EJ; Boxer RB; Hartman JL; Sintasath L; Moody SE; Cox JD; Ha SI; Belka GK; Golant A; Cardiff RD; Chodosh LA
Nat Med; 2001 Feb; 7(2):235-9. PubMed ID: 11175856
[TBL] [Abstract][Full Text] [Related]
11. Interference of mouse polyomavirus with the c-myc gene and its product in mouse mammary adenocarcinomas.
Holländerová D; Raslová H; Blangy D; Forstová J; Berebbi M
Int J Oncol; 2003 Aug; 23(2):333-41. PubMed ID: 12851682
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of cyclin D1 and c-Myc leads to more aggressive and invasive mammary tumors in severe combined immunodeficient mice.
Wang Y; Thakur A; Sun Y; Wu J; Biliran H; Bollig A; Liao DJ
Cancer Res; 2007 Apr; 67(8):3698-707. PubMed ID: 17440082
[TBL] [Abstract][Full Text] [Related]
13. c-Myc inhibits Ras-mediated differentiation of pheochromocytoma cells by blocking c-Jun up-regulation.
Vaqué JP; Fernández-García B; García-Sanz P; Ferrandiz N; Bretones G; Calvo F; Crespo P; Marín MC; León J
Mol Cancer Res; 2008 Feb; 6(2):325-39. PubMed ID: 18314492
[TBL] [Abstract][Full Text] [Related]
14. Leaving home early: reexamination of the canonical models of tumor progression.
Weinberg RA
Cancer Cell; 2008 Oct; 14(4):283-4. PubMed ID: 18835030
[TBL] [Abstract][Full Text] [Related]
15. [The mouse ovarian surface epithelium cells (MOSE) transformation induced by c-myc/K-ras in].
Yao DS; Li L; Garson K; Vanderhyden BC
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):881-5. PubMed ID: 17533735
[TBL] [Abstract][Full Text] [Related]
16. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
Williams K; Fernandez S; Stien X; Ishii K; Love HD; Lau YF; Roberts RL; Hayward SW
Prostate; 2005 Jun; 63(4):369-84. PubMed ID: 15937962
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-alpha inhibits the intrinsic pathway of c-Myc-induced apoptosis through activation of nuclear factor-kappaB in murine hepatocellular carcinomas.
Cavin LG; Wang F; Factor VM; Kaur S; Venkatraman M; Thorgeirsson SS; Arsura M
Mol Cancer Res; 2005 Jul; 3(7):403-12. PubMed ID: 16046551
[TBL] [Abstract][Full Text] [Related]
18. Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis.
Jang JW; Boxer RB; Chodosh LA
Mol Cell Biol; 2006 Nov; 26(21):8109-21. PubMed ID: 16908535
[TBL] [Abstract][Full Text] [Related]
19. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.
Shachaf CM; Kopelman AM; Arvanitis C; Karlsson A; Beer S; Mandl S; Bachmann MH; Borowsky AD; Ruebner B; Cardiff RD; Yang Q; Bishop JM; Contag CH; Felsher DW
Nature; 2004 Oct; 431(7012):1112-7. PubMed ID: 15475948
[TBL] [Abstract][Full Text] [Related]
20. MIF loss impairs Myc-induced lymphomagenesis.
Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
